Mycophenolate mofetil therapy in lupus nephritis: Clinical observations

Journal of the American Society of Nephrology

Volumn 10, Issue 4, 1999, Pages 833-839

  Dooley, Mary Anne ^a   Cosio, Fernando G ^b   Nachman, Patrick H ^a   Falkenhain, Michael E ^b   Hogan, Susan L ^a   Falk, Ronald J ^a   Hebert, Lee A ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; STOMATITIS; TREATMENT OUTCOME;

EID: 0032986483     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Austin HA, Klippel, JH, Balow JE, le Riche NGH, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614-619, 1986
2. Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, Flis R, Pirani C, Appel GB: Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study. Clin Nephrol 42: 71-78, 1994
3. Lehman TJ, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB: Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 114: 1055-1060, 1989
4. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methyl-prednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992
5. Austin AH 3rd, Boumpas DT, Vaughan EM, Balow JE: Highrisk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 19: 1670-1678, 1995
6. Dooley MA, Hogan S, Jennette CJ, Falk RJ: Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Kidney Int 51: 1188-1195, 1997
7. Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD: Systemic lupus erythematosus: Emerging concepts. Part I. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 122: 940-950, 1995
8. Morris RE, Hoyt EG, Murphy MP: Mycophenolic acid morpholinoethylester (RS-61433) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 22: 1659-1662, 1990
9. Eugui EM, Almquist S, Muller CD, Allison AC: Lymphocyte selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scan J Immunol 33: 161-173, 1991
10. Carr SF, Papp E, Wu JC, Natsumeda Y: Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 268: 27286-27290, 1993
11. Allison AC, Eugui EM, Sollinger HW: Mycophenolate mofetil (RS-61443): Mechanism of action and effects in transplantation. Transplant Rev 7: 129-139, 1993
12. Allison AC: Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 26: 3205-3210, 1994
13. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM: Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 25[Suppl 2]: 67-70, 1993
14. Corna D, Morigi M, Faccinetti D, Bertani T, Zoja C, Remuzzi G: Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 51: 1583-1589, 1997
15. Epinette WW, Parker C, Jones L, Greist MC: Mycophenolic acid for psoriasis: A review of pharmacology, long term efficacy, and safety. J Am Acad Dermatol 17: 962-971, 1987
16. Goldblum R: Therapy of rheumatoid arthritis with mycopheno-late mofetil. Clin Exp Rheumatol 11[Suppl]: S117-S119, 1993
17. Zimmer-Molsberger B, Knauf W, Eckhard T: Mycophenolate mofetil for severe autoimmune hemolytic anemia. Lancet 350: 1003-1004, 1997
18. Nowack R, Birck R, van der Woude FJ: Mycophenolate mofetil for systemic vasculitis and IgA nephropathy [Letter]. Lancet 349: 774, 1997
19. Briggs WA, Choi MJ, Scheel PJ: Successful treatment of glomerular disease with mycophenolate mofetil. Am J Kidney Dis 31: 213-217, 1998
20. Tan EM, Cohen AS, Fries J: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277, 1982
21. Sollinger HW, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225-232, 1995
22. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and glucocorticoids for prevention of acute rejection. Lancet 345: 1321-1325, 1995
23. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation 61: 1029-1037, 1996
24. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C: Mycophenolate mofetil in renal allograft recipients. Transplantation 63: 39-47, 1997
25. Franklin CM, Goldblum R, Robinson C, Chiang Y: Dose-ranging, placebo-controlled trial of mycophenolate mofetil (MYC) in refractory rheumatoid arthritis (RA) [Abstract]. Arthritis Rheum 11[Suppl]: S57, 1993
26. McMurray RW, Elbourne KB, Lal S: Mycophenolate mofetil prevents lupus nephritis and mortality in the female B/W mouse model of SLE [Abstract]. Arthritis Rheum 9(Suppl): S324, 1997
27. Mieke CJ, Walgreen B, Rijke TPM, Berden JHM: Mycophenolate mofetil delays lupus nephritis MRL/lpr mice [Abstract]. J Am Soc Nephrol 8: 468A, 1997
28. Moroni, G, Quaglini, S, Maccario, M, Banfi, G, Ponticelli, C: "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 50: 2047-2053, 1996
29. Allison AC, Almquist SJ, Muller CD, Nowak I, Shaw LM: Mycophenolic acid binding to human serum albumen: Characterization and relation to pharmacodynamics. Clin Chem 41: 1011-1017, 1995